Publications in collaboration with researchers from Hospital Universitario de Basurto (45)

2024

  1. BRAF mutational status is associated with survival outcomes in locally advanced resectable and metastatic NSCLC

    Lung Cancer, Vol. 194

  2. Beyond cancer treatment: dermo-aesthetic and other wellness recommendations for breast cancer patients

    Clinical and Translational Oncology

  3. First-line therapy with palbociclib in patients with advanced HR+/HER2− breast cancer: The real-life study PALBOSPAIN

    Breast Cancer Research and Treatment, Vol. 206, Núm. 2, pp. 317-328

  4. Leveraging Large Language Models for Precision Monitoring of Chemotherapy-Induced Toxicities: A Pilot Study with Expert Comparisons and Future Directions

    Cancers, Vol. 16, Núm. 16

  5. Olaparib maintenance versus placebo in platinum-sensitive non-small cell lung cancer: the Phase 2 randomized PIPSeN trial

    British Journal of Cancer, Vol. 130, Núm. 3, pp. 417-424

  6. Thrombosis in breast cancer patients on cyclin-dependent kinase inhibitors: Survival impact and predictive factors - A study by the cancer and thrombosis group of the spanish society of medical oncology (SEOM)

    European Journal of Internal Medicine

2023

  1. Long-term outcomes of high-risk HR-positive and HER2-negative early breast cancer patients from GEICAM adjuvant studies and El Álamo IV registry

    Breast Cancer Research and Treatment, Vol. 201, Núm. 2, pp. 151-159

  2. Narrative Review of Multidisciplinary Management of Central Nervous Involvement in Patients with HER2-Positive Metastatic Breast Cancer: Focus on Elderly Patients

    Advances in Therapy, Vol. 40, Núm. 8, pp. 3304-3331

2022

  1. Do Antiangiogenics Promote Clot Instability? Data from the TESEO Prospective Registry and Caravaggio Clinical Trial

    Thrombosis and haemostasis, Vol. 122, Núm. 10, pp. 1653-1661

  2. Incidence, risk factors, and evolution of venous thromboembolic events in patients diagnosed with pancreatic carcinoma and treated with chemotherapy on an outpatient basis

    European Journal of Internal Medicine, Vol. 105, pp. 30-37

  3. Safety and efficacy of ribociclib plus letrozole in patients with HR+, HER2– advanced breast cancer: Results from the Spanish sub-population of the phase 3b CompLEEment-1 trial

    Breast, Vol. 66, pp. 77-84

2021

  1. Consensus of the Spanish society of laboratory medicine and the Spanish society of medical oncology on the methodology and criteria for evaluation of circulating tumour markers in breast cancer

    Clinical and Translational Oncology, Vol. 23, Núm. 7, pp. 1272-1280

  2. Incidence and clinical pattern of contralateral synchronous and metachronous germ cell testicular cancer

    Urologic Oncology: Seminars and Original Investigations, Vol. 39, Núm. 2, pp. 135.e17-135.e23

  3. Prognostic and therapeutic value of somatic mutations in diffuse large B-cell lymphoma: A systematic review

    Critical Reviews in Oncology/Hematology, Vol. 165

  4. Systematic review of the potential of MicroRNAs in the management of patients with follicular lymphoma

    Critical Reviews in Oncology/Hematology, Vol. 159

2020

  1. Changes in lung cancer survival by TNM stage in the Basque country from 2003 to 2014 according to period of diagnosis

    Cancer Epidemiology, Vol. 65

  2. Probabilistic cost-utility analysis and expected value of perfect information for the Oncotype multigenic test: a discrete event simulation model

    Gaceta Sanitaria, Vol. 34, Núm. 1, pp. 61-68

  3. The economic burden of metastatic breast cancer in Spain

    European Journal of Hospital Pharmacy , Vol. 27, Núm. 1, pp. 19-24

2019

  1. Biological and prognostic differences between symptomatic colorectal carcinomas and those detected by screening

    European Journal of Surgical Oncology, Vol. 45, Núm. 10, pp. 1876-1881

  2. Impact of an osteoporosis specialized unit on bone health in breast cancer survivals treated with aromatase inhibitors

    Reumatologia Clinica, Vol. 15, Núm. 4, pp. 211-217